Terns Pharmaceuticals, Inc. Research and Development Expense of Revenue

Research and Development Expense of Revenue of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Research and Development Expense of Revenue growth rates and interactive chart.


Highlights and Quick Summary

  • Research and Development Expense of Revenue for the quarter ending March 31, 2022 was 0.0% (a -100.0% decrease compared to previous quarter)
  • Year-over-year quarterly Research and Development Expense of Revenue decreased by NaN%
  • Annual Research and Development Expense of Revenue for 2021 was 3131.1% (a Infinity% increase from previous year)
  • Annual Research and Development Expense of Revenue for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual Research and Development Expense of Revenue for 2019 was 0.0% (a NaN% decrease from previous year)
  • Twelve month Research and Development Expense of Revenue ending March 31, 2022 was 0.0% (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Research and Development Expense of Revenue decreased by NaN% year-over-year
Trailing Research and Development Expense of Revenue for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
0.0% 0.0% 0.0% 0.0%
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Research and Development Expense of Revenue of Terns Pharmaceuticals, Inc.

Most recent Research and Development Expense of Revenueof TERN including historical data for past 10 years.

Interactive Chart of Research and Development Expense of Revenue of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Research and Development Expense of Revenue for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.0%
2021 946.2% 0.0% 0.0% 0.0% 3131.1%
2020 0.0% 0.0% 0.0% 0.0% 0.0%
2019 0.0% 0.0%
2018 0.0%

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.